AQR Capital Management
DNLI icon

AQR Capital Management’s Denali Therapeutics DNLI Stock Holding History

AQR Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.99M Buy
388,469
+285,890
+279% +$5.87M ﹤0.01% 1573
2026
Q1 		$1.97M Buy
102,579
+64,141
+167% +$1.28M ﹤0.01% 2352
2025
Q4 		$635K Buy
38,438
+14,299
+59% +$241K ﹤0.01% 2790
2025
Q3 		$350K Buy
24,139
+2,922
+14% +$42K ﹤0.01% 3005
2025
Q2 		$297K Buy
+21,217
New +$299K ﹤0.01% 2880
2024
Q4 		– Sell
-16,018
Closed -$467K – 2890
2024
Q3 		$467K Buy
+16,018
New +$397K ﹤0.01% 2201
2024
Q2 		– Sell
-11,001
Closed -$226K – 2618
2024
Q1 		$226K Buy
+11,001
New +$207K ﹤0.01% 2230
2023
Q3 		– Sell
-8,165
Closed -$241K – 2330
2023
Q2 		$241K Sell
8,165
-1,036
-11% -$29.1K ﹤0.01% 2021
2023
Q1 		$212K Buy
+9,201
New +$253K ﹤0.01% 2038
2022
Q2 		– Sell
-22,686
Closed -$730K – 2203
2022
Q1 		$730K Sell
22,686
-28,981
-56% -$997K ﹤0.01% 1680
2021
Q4 		$2.3M Sell
51,667
-30,382
-37% -$1.44M ﹤0.01% 1090
2021
Q3 		$4.14M Buy
82,049
+2,765
+3% +$156K 0.01% 855
2021
Q2 		$6.22M Sell
79,284
-7,340
-8% -$454K 0.01% 789
2021
Q1 		$4.95M Buy
86,624
+22,757
+36% +$1.52M 0.01% 827
2020
Q4 		$5.35M Buy
63,867
+12,620
+25% +$763K 0.01% 763
2020
Q3 		$1.84M Buy
51,247
+22,370
+77% +$674K ﹤0.01% 1150
2020
Q2 		$698K Buy
28,877
+2,047
+8% +$48.1K ﹤0.01% 1625
2020
Q1 		$470K Sell
26,830
-22,375
-45% -$467K ﹤0.01% 1607
2019
Q4 		$857K Sell
49,205
-19,789
-29% -$329K ﹤0.01% 1563
2019
Q3 		$1.06M Buy
68,994
+58,648
+567% +$1.12M ﹤0.01% 1505
2019
Q2 		$215K Buy
+10,346
New +$232K ﹤0.01% 1968

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management's DNLI Position: Q2 2026 in Review

AQR Capital Management increased its Denali Therapeutics (DNLI) stake by 279% in Q2 2026, buying an estimated $5.87M and bringing the position to 388,469 shares worth $9.99M. The position accounts for ﹤0.01% of the portfolio, ranked #1573.

AQR Capital Management first reported a position in DNLI in Q2 2019 and has held it in 21 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • AQR Capital Management held 388,469 shares of Denali Therapeutics worth $9.99M as of Q2 2026.
  • AQR Capital Management bought 285,890 Denali Therapeutics shares in Q2 2026, an estimated $5.87M.
  • Denali Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #1573 holding.
  • AQR Capital Management first reported a position in Denali Therapeutics in Q2 2019 and has held it in 21 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.